INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)

The INSPIRE trial was a Phase 3, open‐label, multicenter trial (LTI‐301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized treprostinil (Transition) or added Yutrepia to prostacyclin naïve patients on ≤2 nonprostacyclin or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Nicholas S., Feldman, Jeremy P., Sahay, Sandeep, Benza, Raymond L., Preston, Ioana R., Badesch, David, Frantz, Robert P., Patel, Savan, Galloway, Ashley, Bull, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400582/
https://www.ncbi.nlm.nih.gov/pubmed/36034402
http://dx.doi.org/10.1002/pul2.12119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400582/
https://www.ncbi.nlm.nih.gov/pubmed/36034402
http://dx.doi.org/10.1002/pul2.12119

Ejemplares similares